A Single Group Study to Evaluate the Effects of a Multivitamin on a Range of Health and Wellbeing Outcomes.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06568146

Enrollment

Registered

2024-08-23

Start date

2024-05-23

Completion date

2024-10-23

Last updated

2024-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health and Wellbeing

Keywords

Multivitamin, Cognitive Function, Iron, Vitamin D, Vitamin B12, Insulin

Brief summary

This is a hybrid single-group clinical trial that will last 12 weeks. Participants will take 2 capsules daily with the first meal of the day in the morning. Participants will undertake blood tests at Baseline and Week 12. Study-specific questionnaires will be completed at Baseline, Week 4, Week 8, and Week 12. Cognitive Battery Testing will take place at Baseline, Week 4, Week 8, and Week 12.

Interventions

DIETARY_SUPPLEMENTMultivitamin Supplement

: Participants will take 2 capsules of the multivitamin supplement daily with the first meal of the day in the morning.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Masking description

This is an open-label study where no masking will be implemented.

Intervention model description

This is a hybrid single-group clinical trial designed to evaluate the effects of a multivitamin on a range of health and wellbeing outcomes over a 12-week period.

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Female at birth. * Aged 18+. * Interested in supporting their health and wellbeing. * Not planning to introduce or change prescription medications, vitamins, minerals, or supplements one month prior to and during the study. * Generally healthy with no uncontrolled chronic conditions.

Exclusion criteria

* Recent surgeries or invasive treatments. * Introduction of new health-related products in the last 12 weeks. * Allergies to product ingredients or use of Epi-Pen. * Chronic health conditions affecting participation. * Endocrine or glucose-related disorders, including diabetes. * Hematological disorders, including anemia. * Pregnant, breastfeeding, or planning to conceive. * History of substance abuse or recent smoking. * Unwillingness to follow the study protocol. * Participation in other clinical trials.

Design outcomes

Primary

Measure	Time frame	Description
Changes in Blood Levels of Insulin	Baseline and Week 12	This outcome measure will assess the effect of the multivitamin supplement on serum levels of Insulin.
Changes in Blood Levels of Vitamin B12	Baseline and Week 12	This outcome measure will assess the effect of the multivitamin supplement on serum levels of Vitamin B12.
Changes in Blood Levels of Vitamin D	Baseline and Week 12	This outcome measure will assess the effect of the multivitamin supplement on serum levels of Vitamin D.
Changes in Blood Levels of Iron	Baseline and Week 12	This outcome measure will assess the effect of the multivitamin supplement on serum levels of Iron.

Secondary

Measure	Time frame	Description
Participants' Perceptions of Health and Wellbeing	Baseline, Week 4, Week 8, and Week 12	Evaluation of participants' perceptions via a questionnaire exploring the convenience and efficacy of the multivitamin supplement in supporting overall health and wellbeing.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026